Notably, EZH2 has been implicated in regulating RB1, particularly in prostate cancer, where reduced expression of RB1 and TP53 leads to upregulation of EZH2, promoting lineage plasticity and resistance to enzalutamide [18, 19]. This evidence concerns the gene RB1 and prostate cancer.